IASLC 18th World Conference on Lung Cancer, Yokohama, Japan

Xcovery is presenting a poster entitled: eXalt3: First-Line Ensartinib (X396) versus Crizotinib in Advanced ALK-Rearranged NSCLC (eXalt3): A Randomized, Open-Label, Phase 3 Study Yi-Long Wu, Tony S. Mok, Martin Reck, Heather A. Wakelee, Chris Liang, Fenlai Tan, Kimberly Harrow, Vance Oertel, Gary Dukart, Lieming Ding, Leora Horn The overall study objective is to evaluate the efficacy and safety of ensartinib vs crizotinib in patients with […]